Navigation Links
Life Technologies Showcases Leading Technologies for Cancer Research at the AACR Annual Meeting 2012

CARLSBAD, Calif., April 1, 2012 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) will exhibit products across the spectrum of basic, translational and clinical cancer research during the American Association of Cancer Research (AACR) Annual Meeting 2012, taking place March 31 – April 4, in Chicago, Illinois. In addition, several of Life's customers and collaborators will present research findings.

"From basic discovery of biomarkers to validation of new drug targets and the application of genomic sequencing in clinical trials, Life Technologies provides optimized solutions specific for cancer research," said Ronnie Andrews, president of medical sciences at Life Technologies. "We share with our customers a commitment to accelerating our scientific understanding of cancer, driving to a world in which cancer becomes a manageable disease."

DNA sequencing live on the Ion Bus – The Ion Bus offers a unique opportunity to view the game-changing Ion Personal Genome Machine (PGM™) system in action. The Ion Bus will be parked outside the Chicago Hilton at the intersection of Wabash and Balboa streets. The Ion Bus will be open for tours from 6 a.m. to 10 a.m. and 5 p.m. to 9 p.m., April 1 - 3.


Triple negative breast cancer - Triple negative breast tumors, which make up nearly 20 percent of breast cancers, do not respond to treatment with targeted therapies such as Herceptin® (trastuzumab).  To investigate new options for these patients, the first clinical trial of whole-genome sequencing for women with triple negative breast cancer was initiated in March 2010; early results will be presented by John Carpten, Ph.D., head of the Integrated Cancer Genomics Division at the Phoenix-based Translational Genomics Research Institute (TGen) on Monday, April 2 at 10:30 a.m. Life Technologies is supporting the study, which is revealing the diversity of genetic mutations in triple negative tumors.

Semiconductor sequencing of melanoma samples – George Watts, Ph.D., research assistant professor and co-director of the Genomics Shared Service at The University of Arizona Cancer Center, will present a poster demonstrating accurate, cost-effective sequencing of six commonly mutated genes in archived research samples from metastatic melanoma patients using the Life Technologies Ion Personal Genome Machine (PGM™) system.  The authors state that the study represents proof of principle for "next-generation sequencing to provide robust detection of mutations in fixed tumor samples." The poster will be presented April 2, Monday morning, from 8 a.m. to 12 p.m.

AmpliSeq panels accurately identify more than 700 mutations in patient samples – Marilyn Li, Ph.D., professor of molecular and human genetics and director of the Cancer Genetics Lab at Baylor College of Medicine, will present a poster demonstrating use of the Life Technologies Ion AmpliSeq™ cancer panels to sequence 12 archived tumor research samples including FFPE, bone marrow and cell line samples. The authors report that the panel accurately identified all known mutations previously detected using Pyrosequencing or Sanger sequencing and was sensitive enough to detect mutations at frequencies as low as 5% with 99% confidence. The poster will be presented April 3, Tuesday morning from 8 a.m. to 12 p.m.

Single tube, ultra-multiplexed PCR with Ion AmpliSeq™ technology for amplicon resequencing on the Ion Personal Genome Machine™ System – Gianluca Roma, a senior product manager at Life Technologies, will present data highlighting the accuracy, simplicity and speed of mutation detection in research oncology samples using the Ion Personal Genome Machine (PGM™) and Ion AmpliSeq™ cancer panel (see below). Roma will present a poster April 3, Tuesday morning from 8 a.m. to 12 p.m.

New Products:

Life Technologies offers cancer researchers the ability to detect mutations in cancer-associated genes using both PCR and sequencing platforms.

castPCR – TaqMan® Mutation Detection Assays can help detect 44 mutations in three key cancer genes (BRAF, EGFR, and KRAS). In April 2012, Life will expand the number of assays covered by the existing/current research tool to an additional 241 key mutations in another 21 cancer genes. Powered by an innovative technology known as competitive allele-specific TaqMan® PCR (castPCR™ technology), these assays help researchers detect key mutations in the highly heterogeneous samples typical of cancer tissue.

AmpliSeq panels – The Ion AmpliSeq™ Cancer Panel, made available for sale in the fall of 2011, allows scientists to sequence dozens of genes in cancer research samples within several hours, starting with as little as 10 ng of DNA. The panel detects more than 700 mutations across 46 known cancer genes. This week, Life Technologies announced the availability of Ion AmpliSeq™ Custom panels, which will allow researchers to design custom panels for genomic regions up to 250 Kb in size, expanding to 1 Mb later in 2012.

These products are available as Research Use Only, Not for Diagnostic Use.

Visit Life Technologies in Booth #4419 on the Exhibits floor of McCormick Place West. For more information about Life Tech activities at AACR Annual Meeting 2012, please visit:

About Life Technologies

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company with customers in more than 160 countries using its innovative solutions to solve some of today's most difficult scientific challenges. Quality and innovation are accessible to every lab with its reliable and easy-to-use solutions spanning the biological spectrum with more than 50,000 products for translational research, molecular medicine and diagnostics, stem cell-based therapies, forensics, food safety and animal health. Its systems, reagents and consumables represent some of the most cited brands in scientific research including: Ion Torrent™, Applied Biosystems®,  Invitrogen™, GIBCO®, Ambion®, Molecular Probes®, Novex®, and TaqMan®. Life Technologies employs approximately 10,400 people and upholds its ongoing commitment to innovation with more than 4,000 patents and exclusive licenses. LIFE had sales of $3.7 billion in 2011. Visit us at our website:

Life Technologies' Safe Harbor Statement

This press release includes forward-looking statements about Life Technologies' anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

(Logo: )

Life Technologies Contact
Suzanne Clancy
760-717-8294 (mobile)


SOURCE Life Technologies Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cobalt Technologies Hits Key Commercial Milestone with Pretreatment Process Demonstration
2. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
3. Updated: Life Technologies Announces Fourth Quarter and Fiscal Year 2011 Results
4. BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
5. Life Technologies to Present at Barclays Capital Global Healthcare Conference
6. Medisafe 1 Technologies to Start the $1MM Stock Repurchase Program of 10MM Shares up to 10 Cents a Share
7. Spherix to Present at the LHA Life Sciences & Medical Technologies Virtual Conference on February 16
8. BioStorage Technologies to Host Global Sample Management Workshop at Partnerships in Clinical Trials
9. UV Flu Technologies Continues Aggressive Program to Pay off Convertible Debt
10. Generex Announces Patent Award for its Core Vaccine Technologies in Japan
11. FirstMark to Exhibit at Cardiovascular Research Technologies (CRT) 2012 Conference
Post Your Comments:
(Date:1/28/2020)... ... January 28, 2020 , ... ... R&D, today announced the release of Genedata Expressionist ® 13.5 at ... implementation of Multi-Attribute Methods (MAM) for characterizing and monitoring the quality of ...
(Date:1/27/2020)... ... January 27, 2020 , ... Valencell, ... financing from strategic investors led by Halma plc , a FTSE 100 ... TDF Ventures, GII LLC, and WSJ Joshua Fund. A representative from Halma will ...
(Date:1/24/2020)... ... 24, 2020 , ... Sierra Instruments, global leader in mass ... ideal for BioPharm OEMS. Sierra also announces RedyCompactâ„¢ flow meters ... employ high-precision MEMS (Micro-Electro Mechanical Systems) technology utilizing an advanced, ultra-stable no-drift CMOS ...
(Date:1/22/2020)... ... January 21, 2020 , ... ... Taylor as Southern Midwest Region Industrial and Institutional (I&I) Account Manager. Darrell will ... , Darrell brings over 30 years of sales experience working across ...
Breaking Biology Technology:
(Date:1/23/2020)... ... January 23, 2020 , ... GIOSTAR/HEAMGEN has ... stem cells. The red blood cells are made utilizing a bioreactor that ... transfusion therapy and replaces the need for a human blood donor. ...
(Date:1/23/2020)... , ... January 23, 2020 ... ... a new public-private Manufacturing USA initiative, the Advanced Regenerative Manufacturing Institute (ARMI). ... ARMI brings together a consortium of over 100 partner organizations from industry, ...
(Date:1/22/2020)... ... ... announces the new line of high purity powder chemicals filled into multiuse or single-use, ... accurately weighed to 0.001 of a gram. The new line of powder chemicals includes:, ... Carbohydrates , Phosphates , Chelators , Chaotropic Agents ...
Breaking Biology News(10 mins):